Latham & Watkins Advises Underwriter in Cidara Therapeutics’ Public Offering of Common Stock

San Diego company develops novel anti-infectives including immunotherapies.

October 18, 2016

San Diego-based Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, has announced the closing of its previously announced underwritten public offering of 2,475,248 shares of its common stock, plus 277,389 additional shares sold pursuant to the underwriter’s partial exercise of its option to purchase additional shares, each at a price to the public of $10.10 per share. Including this option exercise, the gross proceeds to Cidara from the offering, before deducting underwriting discounts and commissions and other offering expenses, will be approximately $27.8 million. The underwriter has until November 6, 2016 to exercise its option to purchase an additional 93,898 shares of Cidara’s common stock at the public offering price. Latham & Watkins LLP represented the underwriter Cantor Fitzgerald & Co. as the sole book-running manager for the offering with a corporate team led from the firm’s San Diego office by partners Cheston Larson and Michael Sullivan.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.